Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Other Accumulated Expenses (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Other Accumulated Expenses readings, the most recent being $449000.0 for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 1.32% to $449000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $449000.0 through Dec 2025, down 1.32% year-over-year, with the annual reading at $449000.0 for FY2025, 1.32% down from the prior year.
  • Other Accumulated Expenses hit $449000.0 in Q4 2025 for Terns Pharmaceuticals, down from $940000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $940000.0 in Q3 2025 and bottomed at $83000.0 in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $354750.0, with a median of $339000.0 recorded in 2021.
  • Peak annual rise in Other Accumulated Expenses hit 271.08% in 2022, while the deepest fall reached 48.32% in 2022.
  • Terns Pharmaceuticals' Other Accumulated Expenses stood at $358000.0 in 2021, then tumbled by 48.32% to $185000.0 in 2022, then surged by 50.27% to $278000.0 in 2023, then soared by 63.67% to $455000.0 in 2024, then decreased by 1.32% to $449000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Other Accumulated Expenses are $449000.0 (Q4 2025), $940000.0 (Q3 2025), and $461000.0 (Q2 2025).